MA33058B1 - Composition pharmaceutique solide comprenant de l'amlodipine et du losartan avec stabilite amelioree - Google Patents

Composition pharmaceutique solide comprenant de l'amlodipine et du losartan avec stabilite amelioree

Info

Publication number
MA33058B1
MA33058B1 MA34111A MA34111A MA33058B1 MA 33058 B1 MA33058 B1 MA 33058B1 MA 34111 A MA34111 A MA 34111A MA 34111 A MA34111 A MA 34111A MA 33058 B1 MA33058 B1 MA 33058B1
Authority
MA
Morocco
Prior art keywords
amlodipine
losartan
pharmaceutical composition
solid pharmaceutical
improved stability
Prior art date
Application number
MA34111A
Other languages
Arabic (ar)
English (en)
Inventor
Jae Hyun Park
Kyeong Soo Kim
Ho Taek Yim
Ji Hyun Im
Original Assignee
Hanmi Holdings Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42306870&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33058(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Holdings Co Ltd filed Critical Hanmi Holdings Co Ltd
Publication of MA33058B1 publication Critical patent/MA33058B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention porte sur une composition pharmaceutique solide destinée à prévenir ou traiter des troubles cardiovasculaires, comprenant des formes granulaires d'amlodipine et de losartan séparées l'une de l'autre, et sur un agent stabilisant possédant une stabilité au stockage améliorée en raison d'une interaction minimisée entre l'amlodipine et le losartan.
MA34111A 2009-01-23 2009-06-05 Composition pharmaceutique solide comprenant de l'amlodipine et du losartan avec stabilite amelioree MA33058B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20090005840 2009-01-23
KR1020090036011A KR101232296B1 (ko) 2009-01-23 2009-04-24 안정성이 향상된 암로디핀 및 로자탄을 함유하는 고형 약제학적 조성물
PCT/KR2009/003028 WO2010085027A1 (fr) 2009-01-23 2009-06-05 Composition pharmaceutique solide comprenant de l'amlodipine et du losartan avec stabilité améliorée

Publications (1)

Publication Number Publication Date
MA33058B1 true MA33058B1 (fr) 2012-02-01

Family

ID=42306870

Family Applications (3)

Application Number Title Priority Date Filing Date
MA34109A MA33056B1 (fr) 2009-01-23 2009-02-13 Composition pharmaceutique solide comprenant de l'amlodipine et du losartan et son procede de fabrication
MA34111A MA33058B1 (fr) 2009-01-23 2009-06-05 Composition pharmaceutique solide comprenant de l'amlodipine et du losartan avec stabilite amelioree
MA34110A MA33057B1 (fr) 2009-01-23 2009-12-28 Composition pharmaceutique solide comprenant de l'amlodipine et du losartan

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA34109A MA33056B1 (fr) 2009-01-23 2009-02-13 Composition pharmaceutique solide comprenant de l'amlodipine et du losartan et son procede de fabrication

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA34110A MA33057B1 (fr) 2009-01-23 2009-12-28 Composition pharmaceutique solide comprenant de l'amlodipine et du losartan

Country Status (33)

Country Link
US (3) US9161933B2 (fr)
EP (3) EP2413931B1 (fr)
JP (3) JP5658172B2 (fr)
KR (2) KR101232296B1 (fr)
CN (4) CN102292085B (fr)
AR (3) AR070897A1 (fr)
AU (3) AU2009338267B2 (fr)
BR (3) BRPI0924136B8 (fr)
CA (3) CA2749903C (fr)
CL (1) CL2011001781A1 (fr)
CO (3) CO6361905A2 (fr)
CR (3) CR20110450A (fr)
DO (3) DOP2011000231A (fr)
EA (3) EA020103B1 (fr)
EC (1) ECSP11011253A (fr)
ES (3) ES2580777T3 (fr)
HK (1) HK1163539A1 (fr)
HN (2) HN2011002022A (fr)
IL (3) IL214146A0 (fr)
JO (2) JO2981B1 (fr)
MA (3) MA33056B1 (fr)
MX (3) MX349221B (fr)
MY (3) MY173823A (fr)
NI (3) NI201100145A (fr)
NZ (3) NZ594738A (fr)
PE (4) PE20100559A1 (fr)
SA (1) SA110310070B1 (fr)
SG (3) SG173044A1 (fr)
TW (3) TWI404534B (fr)
UA (3) UA102721C2 (fr)
UY (2) UY32388A (fr)
WO (3) WO2010085014A1 (fr)
ZA (3) ZA201106161B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA020103B1 (ru) 2009-01-23 2014-08-29 Ханми Сайенс Ко., Лтд. Твердая фармацевтическая композиция, содержащая амлодипин и лозартан, и способ ее получения
JP6106359B2 (ja) * 2010-12-13 2017-03-29 第一三共ヘルスケア株式会社 ロキソプロフェンナトリウムとビタミンｂ１を含有する固形製剤
JP6041591B2 (ja) * 2011-09-13 2016-12-14 大日本住友製薬株式会社 イルベサルタンとアムロジピンまたはその塩を含有する安定化された医薬組成物
KR101907881B1 (ko) * 2011-12-30 2018-12-11 한미약품 주식회사 로자탄, 암로디핀 및 히드로클로로티아자이드를 포함하는 고정 용량 조합 제형
CN102600146B (zh) * 2012-04-11 2014-10-08 兆科药业（合肥）有限公司 一种盐酸乐卡地平和氯沙坦钾复方制剂及其制备方法
KR101392364B1 (ko) * 2012-04-17 2014-05-07 한국유나이티드제약 주식회사 안정성이 향상된 암로디핀 및 로잘탄을 함유하는 복합제 조성물
JP6160263B2 (ja) * 2012-06-07 2017-07-12 大正製薬株式会社 ロキソプロフェン含有医薬組成物
KR101506148B1 (ko) * 2013-09-24 2015-03-26 대봉엘에스 주식회사 직접 타정할 수 있는 암로디핀 및 로사르탄을 포함하는 약제학적 조성물, 및 이에 의해 제조된 정제
WO2015072700A1 (fr) * 2013-11-15 2015-05-21 Hanmi Pharm. Co., Ltd. Formulation composite comprenant du tadalafil et de l'amlodipine
KR20150056443A (ko) * 2013-11-15 2015-05-26 한미약품 주식회사 타다라필 및 암로디핀을 포함하는 복합제제
KR101910901B1 (ko) * 2013-11-29 2018-10-24 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
KR102369607B1 (ko) 2014-09-30 2022-03-03 한미약품 주식회사 암로디핀 및 로잘탄을 포함하는 고형 약제학적 조성물
CN104610130A (zh) * 2015-01-22 2015-05-13 华东理工常熟研究院有限公司 氨氯地平-棕榈酸离子液体及其制备方法和用途
KR101914930B1 (ko) 2015-03-31 2018-11-05 한미약품 주식회사 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합 제제
WO2017003186A1 (fr) * 2015-06-30 2017-01-05 Hanmi Pharm. Co., Ltd. Formule complexe pharmaceutique comprenant de l'amlodipine, du losartan et de la rosuvastatine
KR101750689B1 (ko) * 2015-09-15 2017-06-26 주식회사 종근당 약제학적 복합제제
CN116637115A (zh) * 2017-05-27 2023-08-25 广州喜鹊医药有限公司 川芎嗪硝酮衍生物组合物在预防和治疗糖尿病并发症疾病中的应用
CN107260735A (zh) * 2017-07-25 2017-10-20 合肥华方医药科技有限公司 生物利用度提高的二氢吡啶类药物组合物
CN107308158A (zh) * 2017-07-28 2017-11-03 合肥华方医药科技有限公司 一种提高非洛地平生物利用度的药物组合物
CN107308159A (zh) * 2017-07-28 2017-11-03 合肥华方医药科技有限公司 一种提高伊拉地平生物利用度药物组合物
JP7166754B2 (ja) * 2017-11-22 2022-11-08 沢井製薬株式会社 ダサチニブ無水物含有製剤
CN108542891A (zh) * 2018-06-07 2018-09-18 董贵雨 一种含有替格瑞洛的固体药物组合物
JP2020090471A (ja) * 2018-12-07 2020-06-11 ニプロ株式会社 アジルサルタン及びアムロジピンを含有する医薬組成物及びその製造方法
KR102233986B1 (ko) * 2019-06-25 2021-03-30 경남과학기술대학교 산학협력단 라푸티딘 및 이르소글라딘을 함유하는 고형 약제학적 조성물 및 이의 제조방법
KR20210074428A (ko) 2019-12-11 2021-06-22 한미약품 주식회사 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합제제
KR20210152943A (ko) 2020-06-09 2021-12-16 한미약품 주식회사 암로디핀, 로사르탄 및 클로르탈리돈을 단층정에 포함하는 심혈관계 질환의 예방 또는 치료용 약제학적 복합제제
CN112274490B (zh) * 2020-11-19 2022-11-22 四川尚锐生物医药有限公司 一种氨氯地平氯沙坦钾复方组合物的制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
AU685898B2 (en) 1993-12-23 1998-01-29 Du Pont Merck Pharmaceutical Company, The Polymorphs of losartan and the process for the preparation of form II of losartan
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
EP1872797A3 (fr) * 1999-08-24 2008-04-02 Medicure International Inc. Traitement des pathologies cardiovasculaires et associées
US20020068740A1 (en) 1999-12-07 2002-06-06 Mylari Banavara L. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications
WO2002002081A1 (fr) * 2000-07-05 2002-01-10 Capricorn Pharma, Inc. Composition semi-solide a fusion rapide, leurs procedes de production et leurs procedes d'utilisation
CA2420844A1 (fr) 2000-08-30 2003-02-28 Sankyo Company, Limited Compositions medicinales utilisees dans la prevention ou le traitement de l'insuffisance cardiaque
AT5874U1 (de) 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
KR100452491B1 (ko) * 2001-03-29 2004-10-12 한미약품 주식회사 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
JP2005509631A (ja) 2001-10-18 2005-04-14 ノバルティス アクチエンゲゼルシャフト Ａｔ１−レセプターアンタゴニストと心臓血管薬から形成される塩
EP1458693A4 (fr) 2001-11-14 2005-02-09 Teva Pharma Formes cristallines amorphes de losartan potassique et leur procede de preparation
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
WO2003101431A1 (fr) 2002-06-04 2003-12-11 J.B. Chemicals & Pharmaceuticals Ltd. Composition pharmaceutique pour systeme a liberation progressive de medicaments
BRPI0407038A (pt) 2003-01-27 2006-01-17 Hanmi Pharm Ind Co Ltd Camsilato de amlodipina amorfo estável, processo para a preparação do mesmo e composição para administração oral deste
EP1648357A2 (fr) * 2003-07-18 2006-04-26 Pneu Medex Inc. Actionneurs a actionnement fluidique et orthoses a dechargement pneumatique
RU2374240C2 (ru) 2003-07-31 2009-11-27 Никокс С.А. Нитрооксипроизводные лозартана, валсартана, кандесартана, телмисартана, эпросартана и олмесартана в качестве блокаторов рецепторов ангиотензина ii для лечения сердечно-сосудистых заболеваний
US20050209288A1 (en) 2004-01-12 2005-09-22 Grogan Donna R Compositions comprising (S)-amlodipine malate and an angiotensin receptor blocker and methods of their use
PT1814527E (pt) * 2004-11-05 2014-01-16 Boehringer Ingelheim Int Comprimido de bicamada compreendendo telmisartan e amlodipina
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
JP5063370B2 (ja) 2005-06-27 2012-10-31 第一三共株式会社 湿式造粒製薬の調製方法
WO2007001067A2 (fr) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Forme posologique solide
JP2009513622A (ja) * 2005-10-27 2009-04-02 ルピン・リミテッド ロサルタンの医薬製剤
KR20080066776A (ko) 2005-11-08 2008-07-16 노파르티스 아게 안지오텐신 ⅱ 수용체 봉쇄제, 칼슘 채널 봉쇄제 및 다른활성 약제의 조합물
RU2426530C2 (ru) * 2005-12-22 2011-08-20 Такеда Фармасьютикал Компани Лимитед Твердый препарат
KR100742432B1 (ko) * 2005-12-27 2007-07-24 한미약품 주식회사 암로디핀 캠실레이트 및 심바스타틴을 포함하는 복합제제,및 이의 제조방법
KR100913791B1 (ko) 2006-07-21 2009-08-26 한미약품 주식회사 (ｓ)-(-)-암로디핀 캠실레이트 또는 이의 수화물 및 이를함유하는 약학적 조성물
US20080051438A1 (en) 2006-08-11 2008-02-28 Shinobu Nagahama Preventive/Therapeutic Compositions Useful for Treating Cardiovascular Diseases
US20080241240A1 (en) 2006-08-24 2008-10-02 Hanall Pharmaceutical Co., Ltd. Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
WO2008023958A1 (fr) 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Composition pharmaceutique combinée à libération contrôlée comprenant de la dihydropyridine, des bloqueurs de canal calcium et des inhibiteurs de l'hgm-coa réductase
WO2008023869A1 (fr) 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. PRÉPARATION PHARMACEUTIQUE COMBINÉE À LIBÉRATION CONTRÔLÉE COMPRENANT DES INHIBITEURS CALCIQUES À BASE DE DIHYDROPYRIDINE ET DES INHIBITEURS DE HMG-CoA RÉDUCTASE
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
KR101247583B1 (ko) * 2006-12-08 2013-03-26 한미사이언스 주식회사 암로디핀 또는 이의 약제학적 허용가능한 염, 및 로자탄또는 이의 약제학적 허용가능한 염을 함유하는 약제학적조성물
EA020103B1 (ru) 2009-01-23 2014-08-29 Ханми Сайенс Ко., Лтд. Твердая фармацевтическая композиция, содержащая амлодипин и лозартан, и способ ее получения

Also Published As

Publication number Publication date
BRPI0924135A2 (pt) 2016-02-10
BRPI0924136B1 (pt) 2019-10-15
BRPI0924137A2 (pt) 2019-09-24
KR20100086913A (ko) 2010-08-02
BRPI0924136B8 (pt) 2021-05-25
EA021763B1 (ru) 2015-08-31
JP2012515767A (ja) 2012-07-12
HN2011002020A (es) 2014-02-03
CR20110450A (es) 2011-11-10
UY32388A (es) 2010-02-26
IL214145A0 (en) 2011-08-31
ZA201106162B (en) 2012-10-31
US8673945B2 (en) 2014-03-18
SG173046A1 (en) 2011-08-29
TW201031404A (en) 2010-09-01
JP2012515768A (ja) 2012-07-12
ZA201106160B (en) 2012-10-31
CR20110449A (es) 2011-11-10
EP2413931A4 (fr) 2012-08-08
UA102720C2 (ru) 2013-08-12
ECSP11011253A (es) 2011-09-30
PE20120428A1 (es) 2012-05-17
WO2010085027A1 (fr) 2010-07-29
KR20100086921A (ko) 2010-08-02
PE20100739A1 (es) 2010-11-19
CA2749903C (fr) 2016-09-06
ES2505116T3 (es) 2014-10-09
TWI395583B (zh) 2013-05-11
NZ594738A (en) 2013-11-29
JP5466716B2 (ja) 2014-04-09
WO2010085047A3 (fr) 2010-11-04
MX349221B (es) 2017-07-19
AR070897A1 (es) 2010-05-12
AU2009338280A1 (en) 2011-09-15
UA102721C2 (uk) 2013-08-12
MY151550A (en) 2014-06-13
CA2749903A1 (fr) 2010-07-29
JO2981B1 (ar) 2016-09-05
MX2011006008A (es) 2011-06-28
BRPI0924136A8 (pt) 2017-10-03
DOP2011000230A (es) 2011-10-15
CN102292084A (zh) 2011-12-21
MX345956B (es) 2017-02-28
AU2009338251A1 (en) 2011-09-15
CN102292085B (zh) 2017-01-18
MX2011006061A (es) 2011-06-24
DOP2011000231A (es) 2011-10-15
EP2391365A4 (fr) 2012-07-25
ZA201106161B (en) 2012-10-31
US20110245302A1 (en) 2011-10-06
HK1163539A1 (en) 2012-09-14
PE20100559A1 (es) 2010-09-12
US9161933B2 (en) 2015-10-20
SG173045A1 (en) 2011-08-29
IL214147A0 (en) 2011-08-31
NI201100144A (es) 2012-11-06
EA201170960A1 (ru) 2012-01-30
MA33057B1 (fr) 2012-02-01
NI201100145A (es) 2012-08-17
IL214146A0 (en) 2011-08-31
NI201100143A (es) 2012-08-17
EA201170959A1 (ru) 2011-12-30
NZ594740A (en) 2013-11-29
CN102292084B (zh) 2014-01-29
EP2391348B1 (fr) 2014-08-27
EA201170958A1 (ru) 2012-01-30
KR101160151B1 (ko) 2012-06-27
CA2749957C (fr) 2016-07-26
MX2011006009A (es) 2011-06-28
CA2749957A1 (fr) 2010-07-29
AU2009338280B2 (en) 2014-05-01
HN2011002022A (es) 2014-02-03
EP2391365A2 (fr) 2011-12-07
NZ594739A (en) 2013-11-29
CA2749955C (fr) 2016-07-26
WO2010085047A2 (fr) 2010-07-29
JO3328B1 (ar) 2019-03-13
JP2012515770A (ja) 2012-07-12
PE20140978A1 (es) 2014-08-16
KR101232296B1 (ko) 2013-02-13
SG173044A1 (en) 2011-08-29
AU2009338267A2 (en) 2011-09-29
AU2009338251B2 (en) 2014-03-13
CO6361915A2 (es) 2012-01-20
CN105998017A (zh) 2016-10-12
ES2580777T3 (es) 2016-08-26
ES2526606T3 (es) 2015-01-13
BRPI0924136A2 (pt) 2017-06-13
EP2413931B1 (fr) 2016-06-01
IL214147A (en) 2016-08-31
CA2749955A1 (fr) 2010-07-29
EA019471B1 (ru) 2014-03-31
EP2391365B1 (fr) 2014-11-26
UY32389A (es) 2010-02-26
US20110245301A1 (en) 2011-10-06
MY150974A (en) 2014-03-31
AR075028A1 (es) 2011-03-02
MX345868B (es) 2017-02-21
CN102292085A (zh) 2011-12-21
MA33056B1 (fr) 2012-02-01
UA105203C2 (ru) 2014-04-25
AR075027A1 (es) 2011-03-02
WO2010085014A1 (fr) 2010-07-29
CR20110448A (es) 2011-11-10
DOP2011000229A (es) 2011-10-15
JP5660544B2 (ja) 2015-01-28
AU2009338267A1 (en) 2011-09-15
TWI404534B (zh) 2013-08-11
AU2009338267B2 (en) 2014-09-18
EP2391348A1 (fr) 2011-12-07
EP2391348A4 (fr) 2012-07-25
CL2011001781A1 (es) 2012-03-23
JP5658172B2 (ja) 2015-01-21
EA020103B1 (ru) 2014-08-29
TW201028151A (en) 2010-08-01
CO6361905A2 (es) 2012-01-20
MY173823A (en) 2020-02-24
CN102292070A (zh) 2011-12-21
SA110310070B1 (ar) 2014-09-02
CO6361914A2 (es) 2012-01-20
US20110251245A1 (en) 2011-10-13
EP2413931A1 (fr) 2012-02-08
US8673944B2 (en) 2014-03-18
ES2580777T8 (es) 2016-09-22

Similar Documents

Publication Publication Date Title
MA33058B1 (fr) Composition pharmaceutique solide comprenant de l'amlodipine et du losartan avec stabilite amelioree
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
WO2010003127A3 (fr) Antagonistes des récepteurs de la prostaglandine d<sb>2</sb>
WO2010039977A3 (fr) Antagonistes d'hétéroaryle des récepteurs de la prostaglandine d2
WO2010057118A3 (fr) Antagonistes hétérocycliques des récepteurs de la prostaglandine d2
WO2009145989A3 (fr) Antagonistes d’aminoalkylphényle de récepteurs de prostaglandine d<sb>2</sb>
WO2010127099A3 (fr) Compositions pharmaceutiques comprenant de l'epa et un agent cardiovasculaire et leurs procédés d'utilisation
JP2009531457A5 (fr)
IN2012DN01233A (fr)
WO2012024620A3 (fr) Inhibiteurs de l'autotaxine et leurs utilisations
WO2012103038A9 (fr) Compositions de nanoparticules, leurs formulations et leurs utilisations
WO2011041729A3 (fr) Composés utiles comme antagonistes du récepteur de l'acide lysophosphatidique (lpa)
WO2011017350A3 (fr) Composés en tant qu'antagonistes du récepteur de l'acide lysophosphatidique
WO2009140642A3 (fr) Antagonistes tricycliques de récepteurs de prostaglandine d<sb>2</sb>
WO2010054113A3 (fr) Antagonistes de cycloalkane[b]azaindole de récepteurs de la prostaglandine d2
EA201001253A1 (ru) N,n-дизамещенные аминоалкилбифенилы в качестве антагонистов рецепторов простагландина d
MY144857A (en) Phamaceutical composition comprising amlodipine and losartan
EA201170703A1 (ru) Производные адамантилбензамида
WO2010085820A3 (fr) Composés tricycliques en tant qu'antagonistes des récepteurs d2 de la prostaglandine
TN2012000524A1 (en) Methods for the prevention and control of pathogenic infections in bees and relative composition
WO2009045291A3 (fr) Stabilisateurs de cellules mast dans le traitement de l'obésité
WO2010083955A3 (fr) Utilisation de composés énaminocarbonylés pour lutter contre des viroses transmises par des insectes
NO20076405L (no) Anvendelse av 24-nor-UDCA
WO2013190497A3 (fr) Compositions et procédés pour le traitement de maladies inflammatoires du poumon
WO2008066770A3 (fr) Composés activateurs de l'ace2 et procédés d'utilisation de ceux-ci